Linagliptin Demo S.A.

Linagliptin, the active ingredient in Linagliptin Demo S.A., is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It belongs to the antidiabetic therapeutic class and improves blood glucose control in adults with type 2 diabetes mellitus by increasing incretin hormone levels and enhancing glucose‑dependent insulin secretion.

GNH USA supplies Linagliptin Demo S.A. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and provides documentation to meet regulatory‑compliant requirements for import and export across EU and international markets.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance. - Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting glucose when used alone. - Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to achieve additional glycemic control. - Patients with renal impairment: can be administered without dose adjustment, providing a convenient option for those with reduced kidney function.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial discomfort. - Gastrointestinal upset: nausea, abdominal pain or diarrhoea. - Upper respiratory tract infection: cough and congestion. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: jaundice or elevated liver enzymes.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal function: monitor kidney status, although dose adjustment is not required. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy: avoid unless the potential benefit justifies the risk, as safety data are limited. - Concomitant antidiabetic agents: adjust doses of insulin or sulfonylureas to reduce hypoglycaemia risk. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Linagliptin can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia, monitor glucose levels. - Diuretics: may alter glucose control, observe patient response. - Warfarin: potential effect on INR, check coagulation parameters regularly.